Drug Profile
Transplant acceptance inducing cells - Fresenius
Alternative Names: TAICLatest Information Update: 03 Jul 2006
Price :
$50
*
At a glance
- Originator Fresenius AG
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 03 Jul 2006 No development reported - Phase-I for Transplant rejection in Germany (IV)
- 24 Feb 2005 Phase-I clinical trials in Transplant rejection in Germany (IV)
- 04 Mar 2004 Preclinical trials in Transplant rejection in Germany (IV)